My Companies
Notification
Account
Log Out
Login
Biocon commercially launched Yesafili™, its interchangeable biosimilar aflibercept 2 mg, in the U.S. on August 3, 2026, targeting the ~$5.9 bn Eylea® market. Context: fulfills the anticipated biosimilar launch catalyst.
Biocon Secures Q1 2027 EU Launch For Pebrilzo After Genentech Settlement
Biocon Secures Japan Marketing Approval For Pegfilgrastim Biosimilar With Sandoz
Biocon Launches Yesafili Aflibercept Biosimilar in United States
Mylan Sells Entire 5.64% Biocon Stake In Open Market Deal